In clinical practice, COMP is regarded as a biomarker for idiopathic pulmonary fibrosis and cartilage degeneration, as well as a prognostic marker for joint damage in rheumatic diseases (Posey et al., 2018). This evidence concerns the gene COMP and idiopathic pulmonary fibrosis.